“Over a few short years, the cell therapy industry has made significant progress with remarkable patient responses to therapy being seen in a few select cancer indications. While encouraging, a significant need still exists for the majority of cancer types where existing cell therapies have not been shown to be effective,” said Dr. Soon-Shiong. “Natural killer cells have potent cancer cell killing capabilities, yet are often overlooked as the immune system’s first line of defense against cancer and other foreign invaders. Without question, cancer patients deserve better treatment options and I welcome the opportunity to present my vision for next generation NK cell therapies at the Summit.”
Presentation Title:Charting a Path to Next Generation Natural Killer Cell Immunotherapies
Dr. Soon-Shiong presentation will be posted on the
For more event information, please visit: https://innate-killer.com/
With the capacity to grow active killer cells as a living cancer therapy, our NK cells have been designed to induce cell death against cancers and virally infected cells by several mechanisms, including: innate killing, whereby all of our NK platforms recognize the stress proteins typically found on cancer cells, which, upon binding, release toxic granules to immediately kill their targets; antibody-mediated killing with our haNK® platform, which are NK cells engineered to express antibody receptors that can bind to therapeutic antibody products, thereby enhancing the cancer cell killing effect of that antibody; and Chimeric Antigen Receptor directed killing using the taNK® platform, which includes NK cells engineered to incorporate chimeric antigen receptors (CARs) to target tumor-specific antigens found on the surface of cancer cells. All three modes of killing (innate, antibody-mediated, and CAR directed killing) are employed by our t-haNK™ platform, which is an innovative combination of our aNK, haNK® and taNK® platforms in a single product.
Our haNK®, and t-haNK™ platforms have been designed to address certain limitations of CAR T-cell therapy including the capability to infuse cell therapy in an outpatient setting which allows for potential reduction of risk for serious cytokine storms and protracted serious adverse events. In Phase I and II clinical trials in patients with late stage cancer, our NK cells have been administered as an investigational outpatient infusion safely with greater than 300 infusions to date at a dose of 2 billion cells per infusion.
By leveraging an integrated and extensive genomics and transcriptomics
discovery and development engine, together with a pipeline of multiple,
clinical-stage, immuno-oncology programs, we believe
NK-92, aNK, haNK, taNK, and t-haNK are trademarks of
NantCell is a privately held immunotherapy company with one of the broadest portfolio of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokines, monoclonal antibodies, adenovirus and yeast vaccine therapies.
This platform of technologies has enabled NantCell to achieve one of the most comprehensive late stage clinical pipelines of an integrated platform of immunotherapy technologies addressing both the innate (activated macrophage and natural killer cell) and the adaptive immune system (dendritic, CD4 and CD8 killer T cells).
The pipeline constitutes over 40 immunological assets with 13 first in human immunotherapy molecules in active clinical trials.
Currently the company is planning the enrollment in 2019 of patients in late stage trials with 3 molecules across 17 indications in solid and liquid tumors.
In the field of oncology, NantCell’s goal is to employ a broad portfolio of biological molecules that will enable it to activate the endogenous NK, CD8+ T cell and develop a T cell memory cancer vaccine to combat multiple tumor types without the use of high-dose chemotherapy.
In the field of infectious disease, NantCell’s goal is to develop vaccine therapy to treat and prevent diseases including HIV, Influenza, Zika, and Ebola.
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning or implying the
Company will be successful in improving the treatment of cancer. Risks
and uncertainties related to this endeavor include, but are not limited
Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements.
These and other risks regarding our business are described in detail in